Clinical Trials on Nodule Solitary Thyroid in Russian Federation

Total 38 results

Yaroslavl State Medical Academy

Terminated

Hemodynamic Parameters in Euthyroid Patients With Thyroid Nodules

Thyroid Nodules

Russian Federation
Saint Petersburg State University, Russia

Withdrawn

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage

Russian Federation
Saint Petersburg State University, Russia

Withdrawn

Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO)

Thyroid Gland Anaplastic Carcinoma

Russian Federation
Saint Petersburg State University, Russia

Recruiting

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Anaplastic Thyroid Cancer

Russian Federation
Saint Petersburg State University, Russia

Recruiting

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

Anaplastic Thyroid Cancer

Russian Federation
Saint Petersburg State University, Russia

Completed

Lidocaine And Neuromonitoring in Thyroid Surgery

Anesthesia | Parathyroid Neoplasms | Thyroid Neoplasm

Russian Federation
S.LAB (SOLOWAYS)
Center of New Medical Technologies

Not yet recruiting

Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G/A SEPP1 Polymorphism (ZEST-PREP)

Thyrotoxicosis

Russian Federation
Eisai Inc.

Completed

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

Thyroid Cancer

United States, France, Ukraine, Peru, Russian Federation, Argentina
Saint Petersburg State University, Russia

Not yet recruiting

A Prospective Single-center Cohort Study "Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients"

Breast Neoplasms | Sentinel Lymph Node

Russian Federation
Genzyme, a Sanofi Company

Active, not recruiting

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Thyroid Cancer

United States, Italy, Poland, Russian Federation, United Kingdom, Netherlands, Israel, Czechia, India
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Cervical Cancer | Small Cell Lung Carcinoma | Neuroendocrine Tumor | Advanced Solid Tumors | Mesothelioma | Vulvar Cancer | Cholangiocarcinoma | Bile Duct Cancer | Endometrial Cancer | Advanced Cancer | Cervical Carcinoma | Endometrial Carcinoma | Thyroid Carcinoma | Thyroid Cancer | Anal Cancer | Colorectal Carcinoma | Carcinoid... and other conditions

Canada, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Taiwan, United States, Brazil, Colombia, Israel, Korea, Republic of, Norway, Philippines, South Africa, Spain, Australia, Denmark, Chile, Portugal, Peru
Moscow City Oncology Hospital No. 62

Completed

[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer (SENTRY)

Endometrial Neoplasms | Endometrial Cancer | Sentinel Lymph Node | Endometrial Endometrioid Adenocarcinoma | Endometrial Adenocarcinoma | Hysterectomy | Endometrial Cancer Stage I | Laparoscopic Hysterectomy | Endometrial Cancer Stage II

Russian Federation
Bayer

Completed

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors (RIFTOS MKI)

Thyroid Neoplasms

United States, Japan, Turkey, Russian Federation, India, Germany, France, Mexico, Philippines, Greece, Netherlands, Spain, Taiwan, Brazil, Egypt, Argentina, Algeria, Lebanon, Saudi Arabia
Mateon Therapeutics

Terminated

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer (FACT)

Anaplastic Thyroid Cancer

United States, India, Belarus, Bulgaria, Egypt, Israel, Italy, Poland, Romania, Russian Federation, Ukraine, United Kingdom
Genzyme, a Sanofi Company

Active, not recruiting

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment (88)

Medullary Thyroid Cancer | Locally Advanced or Metastatic Medullary Thyroid Cancer

Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, Germany, Greece, India, Israel, Italy, Korea, Republic of, Poland, Russian Federation, Sweden, United Kingdom
Genzyme, a Sanofi Company

Completed

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer (VERIFY)

Differentiated Thyroid Cancer

United States, Sweden, Brazil, Italy, Poland, Spain, China, Russian Federation, France, Japan, Denmark, Czechia
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Thyroid Cancer

United States, Canada, Germany, Korea, Republic of, Spain, France, Australia, Belgium, Denmark, Israel, Italy, Poland, Romania, Russian Federation, Sweden, United Kingdom
Exelixis

Active, not recruiting

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)

Medullary Thyroid Cancer

Australia, France, Israel, Spain, Russian Federation, Netherlands, Hungary, Korea, Republic of, Croatia, Italy, Canada, Poland, Romania, Sweden
Exelixis

Completed

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM)

Thyroid Cancer

France, United Kingdom, United States, Spain, Austria, Israel, Portugal, Saudi Arabia, Netherlands, Greece, Canada, Brazil, Chile, Poland, Italy, Russian Federation, Sweden, Germany, Denmark, India, Switzerland, Belgium, Korea, Republic... and more
Bayer
Amgen

Completed

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Thyroid Neoplasms

France, China, Korea, Republic of, United States, Spain, Russian Federation, United Kingdom, Netherlands, Sweden, Austria, Italy, Bulgaria, Poland, Saudi Arabia, Germany, Japan, Belgium, Denmark
Genzyme, a Sanofi Company

Active, not recruiting

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Thyroid Cancer

United States, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Spain, Sweden, Switz...
Exelixis
Ipsen

Active, not recruiting

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Differentiated Thyroid Cancer

Hong Kong, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Croatia, Czechia, France, Germany, Hungary, Israel, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Spain, Taiwan, ... and more
Eisai Inc.

Completed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) (SELECT)

Thyroid Cancer

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Thailand, United Kingdom
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Medullary Thyroid Cancer

United States, Canada, Spain, China, Taiwan, Australia, Japan, India, Belgium, Germany, France, Netherlands, Czechia, Brazil, Korea, Republic of, United Kingdom, Italy, Israel, Greece, Poland, Russian Federation
Merz Pharmaceuticals GmbH

Completed

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability (SIPEXI)

Stroke | Cerebral Palsy | Intellectual Disability | Traumatic Brain Injury | Chronic Troublesome Sialorrhea

Georgia, Hungary, Poland, Russian Federation, Serbia, Ukraine
Medtronic Cardiac Rhythm and Heart Failure

Completed

Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady) (IMPROVE Brady)

Sinus Node Dysfunction

Peru, Bangladesh, India, Mexico, Argentina, Russian Federation, Uruguay
Supernus Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects (MYSTICOL)

Sialorrhea

United States, Ukraine, Russian Federation
Medtronic Bakken Research Center

Completed

PANORAMA Observational Study

Heart Failure | Heart Block | Arrhythmia | Sinus Node Disease

Belgium, Russian Federation, Former Serbia and Montenegro, India, Kuwait, Saudi Arabia
Biocad

Completed

Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma

Splenic Marginal Zone Lymphoma | Nodal Marginal Zone Lymphoma | Follicular Non-Hodgkin's Lymphoma

India, Russian Federation, Colombia, South Africa, Ukraine
AstraZeneca

Recruiting

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5

Canada, Spain, China, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia
Novartis Pharmaceuticals

Completed

Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

Choroidal Neovascularization (CNV)

Korea, Republic of, Germany, Russian Federation, Turkey, Australia, Hungary, Switzerland, Italy, Lithuania, Denmark, Peru, Spain, Portugal, Canada, France, Latvia, Greece, Slovakia, Czech Republic, Poland, Singapore
Bristol-Myers Squibb

Terminated

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Sjögren's Syndrome

Australia, United States, Italy, Mexico, Colombia, Peru, Puerto Rico, South Africa, Chile, Poland, Russian Federation
Novartis Pharmaceuticals

Completed

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (TREND)

Age-related Macular Degeneration | Choroidal Neovascularization

Korea, Republic of, Croatia, Germany, India, Russian Federation, Turkey, United Kingdom, Egypt, Israel, Belgium, Denmark, Hungary, Slovenia, Spain, Switzerland, Italy, Portugal, Slovakia, Chile
Novartis Pharmaceuticals

Completed

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Primary Sjogren Syndrome

United States, Belgium, Italy, Austria, Israel, France, Germany, Hungary, Netherlands, United Kingdom, Japan, Portugal, Argentina, Spain, Taiwan, Russian Federation, Romania, Chile, Poland
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome (TWINSS Extn)

Sjogren's Syndrome

United Kingdom, Netherlands, Australia, Austria, Israel, France, Germany, Greece, Hungary, Italy, United States, Korea, Republic of, Japan, Portugal, Russian Federation, Turkey, Canada, Colombia, Romania, Argentina, Chile, Brazil, S...
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome (TWINSS)

Sjögren Syndrome

United States, United Kingdom, Netherlands, Australia, Austria, Israel, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Japan, Portugal, Russian Federation, Turkey, Canada, Colombia, Romania, Argentina, Chile, Brazil, S...
Edgar Jaeggi
Labatt Family Heart Centre

Recruiting

Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia (FAST Registry)

Atrial Flutter | Tachycardia, Supraventricular | Tachycardia, Atrioventricular Nodal Reentry | Tachycardia Atrial | Tachycardia, Reciprocating | Tachycardia, Paroxysmal | Fetal Hydrops | Tachycardia, Atrial Ectopic

United States, Hong Kong, Canada, Netherlands, Sweden, Australia, Brazil, Finland, France, Russian Federation, Spain, Czechia, Switzerland, United Kingdom
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation

Clinical Trials on Nodule Solitary Thyroid in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations